Corrigendum to ‘Avutometinib and defactinib: a novel dual pathway inhibition strategy for recurrent KRAS-mutant low-grade serous ovarian cancer’ International Journal of Gynecological Cancer Volume 36 Issue 5 (2026) 104635 | Synapse
June 15, 2026International Journal of Gynecological Cancer0 citationsOpen Access
Corrigendum to ‘Avutometinib and defactinib: a novel dual pathway inhibition strategy for recurrent KRAS-mutant low-grade serous ovarian cancer’ International Journal of Gynecological Cancer Volume 36 Issue 5 (2026) 104635
The aim is to correct and update specific details of a prior publication on dual pathway inhibition for cancer treatment.
Updates reflect alignment with final published RAMP 201 study data.
Revisions include correction of data presentation.
Focus remains on targeting KRAS-mutant low-grade serous ovarian cancer.
The corrected data provides clarity on the efficacy of dual inhibitors.
Findings adjust previous interpretations of treatment outcomes.
Updated figures support ongoing research in ovarian cancer therapies.
Abstract
The authors wish to revise certain aspects of the article to ensure alignment with the final published RAMP 201 study data. The paragraph below has been updated to reflect the new data and should read: